Shanghai Lianbio Development

LianBio is a biotechnology company founded by Perceptive Advisors with a mission to bridge the gap between global biopharmaceutical innovation and the healthcare needs of patients in China and other major Asian markets. The company specialized in in-licensing late-stage product candidates and developing them through clinical trials and commercialization within its target territories. Its portfolio spanned multiple therapeutic areas, including cardiovascular, oncology, ophthalmology, and inflammatory diseases, featuring high-profile assets like mavacamten and infigratinib. In February 2024, LianBio announced a board-approved plan to wind down its operations, which included selling off remaining pipeline rights and returning capital to shareholders. This strategic shift followed the successful divestment of its lead cardiovascular asset back to Bristol Myers Squibb.